Rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a subgroup analysis of the ROCKET AF trial
JL Halperin, Z Bloomgarden, A Hellkamp… - 2012 - Am Heart Assoc
Background: In patients with nonvalvular AF enrolled in ROCKET AF, rivaroxaban was
noninferior to warfarin for prevention of stroke and systemic embolism and caused less …
noninferior to warfarin for prevention of stroke and systemic embolism and caused less …
[HTML][HTML] Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition …
S Bansilal, Z Bloomgarden, JL Halperin… - American Heart …, 2015 - Elsevier
Background The prevalence of both atrial fibrillation (AF) and diabetes mellitus (DM) are
rising, and these conditions often occur together. Also, DM is an independent risk factor for …
rising, and these conditions often occur together. Also, DM is an independent risk factor for …
Effectiveness and safety of rivaroxaban vs warfarin in people with non‐valvular atrial fibrillation and diabetes: an administrative claims database analysis
CI Coleman, TJ Bunz, D Eriksson… - Diabetic …, 2018 - Wiley Online Library
Aim To assess the effectiveness and safety of rivaroxaban vs warfarin in people with non‐
valvular atrial fibrillation and diabetes treated in routine practice. Methods Using US …
valvular atrial fibrillation and diabetes treated in routine practice. Methods Using US …
The safety and efficacy of rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a systematic review and meta-analysis
Y Hua, JY Sun, Y Su, Q Qu, HY Wang, W Sun… - American Journal of …, 2021 - Springer
Aims This meta-analysis was conducted to compare the efficacy and safety of rivaroxaban
with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus. Methods PubMed …
with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus. Methods PubMed …
[HTML][HTML] Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
CI Coleman, OS Costa, CW Brescia, B Vardar… - Cardiovascular …, 2021 - Springer
Background Diabetes increases a patient's risk of developing atrial fibrillation by 49%.
Patients with nonvalvular atrial fibrillation are at a fivefold increased risk of stroke and die …
Patients with nonvalvular atrial fibrillation are at a fivefold increased risk of stroke and die …
Is there a preferred stroke prevention strategy for diabetic patients with non-valvular atrial fibrillation? Comparing warfarin, dabigatran and rivaroxaban
Background The prevalence of diabetes is growing, and diabetes is an independent risk
factor for both atrial fibrillation (AF) and stroke. However, the relative effectiveness and safety …
factor for both atrial fibrillation (AF) and stroke. However, the relative effectiveness and safety …
[HTML][HTML] Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes
MR Weir, YW Chen, J He, B Bookhart… - Journal of Diabetes and …, 2021 - Elsevier
Aims To compare clinical outcomes of rivaroxaban and warfarin in patients with nonvalvular
atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods Patients aged≥ 18 …
atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods Patients aged≥ 18 …
Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non‐valvular atrial fibrillation and …
WL Baker, J Beyer‐Westendorf, TJ Bunz… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aims To assess the effectiveness and safety of rivaroxaban versus warfarin for the
prevention of major adverse cardiovascular events (MACE) and major adverse limb events …
prevention of major adverse cardiovascular events (MACE) and major adverse limb events …
[HTML][HTML] Comparison of the incidence of major bleeding with rivaroxaban use among nonvalvular atrial fibrillation patients with versus without diabetes mellitus
WF Peacock, S Tamayo, N Sicignano, KP Hopf… - The American Journal of …, 2017 - Elsevier
Diabetes mellitus (DM) is a common co-morbidity in those with nonvalvular atrial fibrillation
(NVAF). Most patients with DM and NVAF have a CHA 2 DS 2-VASc score of≥ 1 and should …
(NVAF). Most patients with DM and NVAF have a CHA 2 DS 2-VASc score of≥ 1 and should …
Effectiveness and safety of apixaban versus rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus
KR Chowdhury, J Michaud, OHY Yu… - Thrombosis and …, 2022 - thieme-connect.com
Aims To evaluate the effectiveness and safety of apixaban versus rivaroxaban among
patients with nonvalvular atrial fibrillation (NVAF) and type 2 diabetes mellitus (T2DM) …
patients with nonvalvular atrial fibrillation (NVAF) and type 2 diabetes mellitus (T2DM) …